ArticleFrontiers in pediatrics2026
Antibiotic exposure for suspected early-onset sepsis in late-preterm and full-term newborns in Quebec: a 11-year single-center cohort study.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antibiotic exposure during the first postnatal week is common among late-preterm and term newborns and represents an important target for neonatal antimicrobial stewardship. We aimed to quantify antibiotic exposure, assess temporal trends, and determine the incidence and mortality of culture-proven early-onset sepsis (CP-EOS) in a Canadian tertiary care center. Methods: This retrospective cohort study included all inborn neonates ≥34 weeks' gestation born at a Canadian tertiary care center between 2013 and 2023. Data were extracted from electronic medical records and institutional microbiology and pharmacy databases. Primary outcomes were antibiotic exposure during the first postnatal week and treatment duration. Secondary outcomes included the incidence and mortality of CP-EOS. Antibiotic exposure indicators were calculated using standardized international benchmarking metrics. Results: Among 34,668 late-preterm and term newborns born during the study period, 1,824 (5.3%; 95% CI, 4.5%-6.0%) received intravenous antibiotics during the first postnatal week for suspected early-onset sepsis (EOS). The median (IQR) antibiotic duration was 3 (3-4) days overall, 9 (5-14) days among neonates with CP-EOS, and 3 (3-5) days among those without proven EOS. Overall antibiotic exposure corresponded to 238 (IQR, 218-259) antibiotic days per 1,000 livebirths. CP-EOS incidence was 0.55 per 1,000 livebirths (95% CI, 0.24-0.83). Overall, for each confirmed EOS case, 96 newborns received antibiotics, and 433 antibiotic days were administered. Conclusions: Antibiotic exposure substantially exceeded the burden of CP-EOS. Standardized benchmarking indicators may help guide neonatal antimicrobial stewardship efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.